383 related articles for article (PubMed ID: 33259803)
1. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.
Roudko V; Bozkus CC; Orfanelli T; McClain CB; Carr C; O'Donnell T; Chakraborty L; Samstein R; Huang KL; Blank SV; Greenbaum B; Bhardwaj N
Cell; 2020 Dec; 183(6):1634-1649.e17. PubMed ID: 33259803
[TBL] [Abstract][Full Text] [Related]
2. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution.
Ballhausen A; Przybilla MJ; Jendrusch M; Haupt S; Pfaffendorf E; Seidler F; Witt J; Hernandez Sanchez A; Urban K; Draxlbauer M; Krausert S; Ahadova A; Kalteis MS; Pfuderer PL; Heid D; Stichel D; Gebert J; Bonsack M; Schott S; Bläker H; Seppälä T; Mecklin JP; Ten Broeke S; Nielsen M; Heuveline V; Krzykalla J; Benner A; Riemer AB; von Knebel Doeberitz M; Kloor M
Nat Commun; 2020 Sep; 11(1):4740. PubMed ID: 32958755
[TBL] [Abstract][Full Text] [Related]
3. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.
Roudko V; Cimen Bozkus C; Greenbaum B; Lucas A; Samstein R; Bhardwaj N
Front Immunol; 2021; 12():757804. PubMed ID: 34630437
[TBL] [Abstract][Full Text] [Related]
4. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
6. The Immune Biology of Microsatellite-Unstable Cancer.
Kloor M; von Knebel Doeberitz M
Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
[TBL] [Abstract][Full Text] [Related]
9. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
[TBL] [Abstract][Full Text] [Related]
10. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
11. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
12. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
[TBL] [Abstract][Full Text] [Related]
13. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
Bauer K; Nelius N; Reuschenbach M; Koch M; Weitz J; Steinert G; Kopitz J; Beckhove P; Tariverdian M; von Knebel Doeberitz M; Kloor M
Cancer Immunol Immunother; 2013 Jan; 62(1):27-37. PubMed ID: 22729559
[TBL] [Abstract][Full Text] [Related]
14. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes.
Garbe Y; Maletzki C; Linnebacher M
PLoS One; 2011; 6(11):e26517. PubMed ID: 22110587
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Heterogeneity of Frameshift Mutations in MECOM Gene is Frequent in Colorectal Cancers with High Microsatellite Instability.
Choi EJ; Kim MS; Song SY; Yoo NJ; Lee SH
Pathol Oncol Res; 2017 Jan; 23(1):145-149. PubMed ID: 27620344
[TBL] [Abstract][Full Text] [Related]
16. Frameshift Mutations of AKAP9 Gene in Gastric and Colorectal Cancers with High Microsatellite Instability.
Jo YS; Kim MS; Yoo NJ; Lee SH
Pathol Oncol Res; 2016 Jul; 22(3):587-92. PubMed ID: 26786868
[TBL] [Abstract][Full Text] [Related]
17. Semiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responses.
Garbe Y; Klier U; Linnebacher M
BMC Cancer; 2011 Sep; 11():410. PubMed ID: 21943054
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.
Scheel SK; Porzner M; Pfeiffer S; Ormanns S; Kirchner T; Jung A
BMC Cancer; 2010 Aug; 10():413. PubMed ID: 20696052
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
20. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.
Saeterdal I; Bjørheim J; Lislerud K; Gjertsen MK; Bukholm IK; Olsen OC; Nesland JM; Eriksen JA; Møller M; Lindblom A; Gaudernack G
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13255-60. PubMed ID: 11687624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
